MedPath

Effect of vitamin D deficiency correction on serum Fibroblast growth factor 23 level

Not Applicable
Conditions
Vitamin D deficiency.
Vitamin D deficiency
Registration Number
IRCT138707171312N1
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

Vitamin D deficient patients (serum vitamin D level under 20 ng/ml) in both sexes and in range 15-90 years old were included in this study. patients who had underlying diseases such as osteomalacia, renal failure,hyperparathyroidism; hypoparathyroidism; osteoporesis; hereditary bone disease such as autosomal dominant hypophosphatemic rickets; autosomal recessive hypophosphatemic rickets, vitamin D resistant rickets; vitamin D dependent rickets; X- linked hypophosphatemia autosomal recessive hypophosphatemia and fibrous dysplasia; recent consumption of calcium supplement; concurrent use of drugs that interfere with vitamin D such as iron supplement; Alluminum and Magnesium admixture such as anti acid drugs; proton pump inhibitors (PPI) like Omeprazole or pantoprazole; bile acid binding resins like cholestyramine; cardiac glycosides such as Digoxin; Danazole; Multi vitamin and minerals; Sucralfate;Orlistat;Thiazide diuretic; alcohol consumption; consumption of other analogs of vitamin D; Herbal drugs; use of Olive; pregnant and lactating women were exclude from the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
FGF23. Timepoint: Basal and 3 month after. Method of measurement: blood sample.
Secondary Outcome Measures
NameTimeMethod
Calcium. Timepoint: Basal and 3 month after. Method of measurement: blood sample.
© Copyright 2025. All Rights Reserved by MedPath